Ruttenberg D, Young G O, Wright J P, Isaacs S
Gastrointestinal Clinic, Department of Medicine, University of Cape Town, South Africa.
Dig Dis Sci. 1992 May;37(5):705-8. doi: 10.1007/BF01296426.
An altered small bowel permeability may be implicated in the pathogenesis of Crohn's disease. Intestinal permeability, using polyethylene glycol 400 (PEG 400) as the orally ingested probe, was assessed in 45 patients with Crohn's disease (ileal N = 14, ileocolonic N = 9, colonic N = 10, postresection N = 12), 20 first-degree relatives, and 31 controls. PEG 400 excretion was measured using a direct injection HPLC method, and results are expressed as percent of dose recovered in urine (median and range). No quantitative differences in the recovery of PEG-400 were found [Crohn's patients 21.9% (6.1-39.9), relatives 23.7% (4.9-39.9), controls 25.0% (4.5-39.7)]. In all groups, the composition of ingested and recovered PEG-400 was similar and no selective permeability to any molecular weight species was found. Disease site did not influence probe recovery [ileal 23.8% (7.7-30.6), ileocolonic 22.6% (14.4-33.8), colonic 27.8% (9.5-33.5)]. Resected patients had significantly lower PEG-400 recovery [18.8% (8.1-39.9)] than nonresected patients [23.5% (6.1-33.8%) P less than 0.02]. The data suggest either that altered intestinal permeability is not a factor in Crohn's disease or that PEG-400 is not a suitable probe.
小肠通透性改变可能与克罗恩病的发病机制有关。以聚乙二醇400（PEG 400）作为口服探针，对45例克罗恩病患者（回肠型n = 14，回结肠型n = 9，结肠型n = 10，切除术后n = 12）、20名一级亲属和31名对照者的肠道通透性进行了评估。采用直接进样高效液相色谱法测定PEG 400排泄量，结果以尿中回收剂量的百分比表示（中位数和范围）。未发现PEG - 400回收率存在定量差异[克罗恩病患者21.9%（6.1 - 39.9），亲属23.7%（4.9 - 39.9），对照者25.0%（4.5 - 39.7）]。在所有组中，摄入和回收的PEG - 400组成相似，未发现对任何分子量物质有选择性通透性。病变部位不影响探针回收率[回肠型23.8%（7.7 - 30.6），回结肠型22.6%（14.4 - 33.8），结肠型27.8%（9.5 - 33.5）]。切除术后患者的PEG - 400回收率[18.8%（8.1 - 39.9）]显著低于未切除患者[23.5%（6.1 - 33.8%），P < 0.02]。数据表明，要么肠道通透性改变不是克罗恩病的一个因素，要么PEG - 400不是一个合适的探针。
